The Emirates Drug Corporation announced today the adoption of the “Rilzabrutinib”, the first oral inhibitory for the Tyrusin Kenaz proton for the treatment of immunodeficiency disease (ITP), a rare immune disorder that affects between 2 to 5 individuals out of every 100,000 people around the world. This achievement is a global precedence that reflects the leadership of the Emirates in accelerating the availability of innovative treatments and meeting the medical needs of patients. The adoption of this drug acquires exceptional importance, as it gives immunosuppressive patients in the UAE and the region an early opportunity to benefit from an innovative treatment that contributes to accelerating their therapeutic path and achieving tangible improvement in the quality of their lives. This step comes within the framework of the state’s commitment
source
